INHIBRX BIOSCIENCES, INC. Capital Expenditures
INHIBRX BIOSCIENCES, INC. (INBX) reported Capital Expenditures of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $0.00.
- INHIBRX BIOSCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $10.00K, a 95.95% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. payments to acquire property, plant, and equipment for fiscal 2025 was $31.00K, a 98.81% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. payments to acquire property, plant, and equipment for fiscal 2024 was $2.60M, a 43.46% decline from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. payments to acquire property, plant, and equipment for fiscal 2023 was $4.59M.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $10.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $10.00K derived: sum of 3 quarters · filed 2026-05-14 | $10.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $10.00K derived: sum of 2 quarters · filed 2026-03-19 | $10.00K derived: sum of 3 quarters · filed 2026-08-13 | $31.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $10.00K derived: sum of 2 quarters · filed 2026-08-13 | $31.00K 10-Q · filed 2025-11-14 | $47.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $21.00K 10-Q · filed 2026-08-13 | $37.00K derived: sum of 3 quarters · filed 2026-08-13 | $284.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $21.00K 10-Q · filed 2026-05-14 | $37.00K derived: sum of 2 quarters · filed 2026-05-14 | $284.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.50M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $263.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.48M derived: sum of 3 quarters · filed 2026-03-19 | $2.60M 10-K · filed 2026-03-19 |
| 2024-09-30 | $247.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.46M derived: sum of 2 quarters · filed 2025-11-14 | $2.58M 10-Q · filed 2025-11-14 | $6.02M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $2.33M 10-Q · filed 2025-08-13 | $5.78M derived: sum of 3 quarters · filed 2025-08-13 | $6.59M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $1.12M 10-Q · filed 2025-05-14 | $4.56M derived: sum of 2 quarters · filed 2025-05-14 | $5.37M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $4.25M derived: sum of 2 quarters · filed 2025-03-17 | $4.59M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $811.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.15M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $340.00K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |